Hemanth Hampole, MD
Nephrology · Katy, TXNPI 1295042471
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.
Across 285 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Mallinckrodt Hospital Products Inc.$717
- Medtronic$610
- Amgen$586
- Novartis$441
- Vifor Pharma, Inc.$402
- plus $3K from 26 others
Across 9 payments — averaging $1888.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$17K
What the payments were for
- Travel & lodging$2964%
- Food & beverage$6,30793%
- Education$1552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 67 | $1,319 |
| Mallinckrodt Hospital Products Inc. | 30 | $717 |
| Medtronic | 7 | $610 |
| Amgen(2 entities) | 30 | $586 |
| Novartis | 16 | $441 |
| Vifor Pharma, Inc. | 20 | $402 |
| Otsuka America Pharmaceutical, Inc. | 18 | $394 |
| Bayer | 12 | $329 |
| Calliditas Therapeutics US Inc. | 17 | $300 |
| Aurinia Pharma U.S., Inc. | 6 | $228 |
| Travere Therapeutics, Inc. | 8 | $159 |
| ANI Pharmaceuticals, Inc. | 7 | $156 |
| Boehringer Ingelheim | 3 | $148 |
| Akebia Therapeutics Inc | 8 | $122 |
| Bard Peripheral Vascular, Inc. | 3 | $104 |
| OPKO Pharmaceuticals, LLC | 5 | $81 |
| Ardelyx, Inc. | 3 | $80 |
| Medline Industries LP | 3 | $64 |
| Johnson & Johnson | 3 | $59 |
| Angiodynamics, Inc. | 1 | $57 |
| Merck | 2 | $54 |
| Abbott | 2 | $51 |
| Lilly USA, LLC | 2 | $48 |
| GSK | 2 | $46 |
| Fresenius USA Marketing, Inc. | 2 | $44 |
| Cook Medical LLC | 2 | $36 |
| Philips North America LLC | 1 | $28 |
| Novo Nordisk | 1 | $25 |
| Boston Scientific | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Sanofi | 1 | $17 |
| Argon Medical Devices, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELLIPSYS VASCULAR ACCESS SYSTEM$496
- LUPKYNIS$125
- JARDIANCE$106
How this compares
$6,759 in reported general payments places this provider in the 80th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 132 | $117,095 |
| KerendiaFinerenone | 16 | $16,754 |
| Sevelamer Carbonate | 30 | $5,979 |
| Potassium Chloride | 17 | $3,302 |
| Calcium Acetate | 21 | $1,833 |
| ProcritEpoetin Alfa | 15 | $1,418 |
| Furosemide | 103 | $645 |
| Nifedipine ErNifedipine | 17 | $579 |
| Telmisartan | 22 | $519 |
| Metolazone | 21 | $445 |
| Hydralazine Hcl | 35 | $407 |
| Carvedilol | 73 | $347 |
| Losartan Potassium | 36 | $291 |
| Amlodipine Besylate | 44 | $268 |
| Metoprolol Succinate | 12 | $256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,319 | $117,095132 claims |
| BayerKerendia | $329 | $16,75416 claims |
| Johnson & JohnsonProcrit | $59 | $1,41815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Katy
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.